#USA #Oklahoma City #blood pressure #Biozen #ACC 2026

Biozen Clinches People's Choice Award at ACC 2026

Biozen, LLC has made headlines by winning the 2026 People’s Choice Award at the American College of Cardiology (ACC) Future Hub Innovation Pitch Challenge. This prestigious event took place on March 29, 2026, during the ACC Scientific Sessions held in New Orleans. The recognition was a testament to Biozen’s innovative approach in the realm of cardiovascular technology, particularly its revolutionary cuffless blood pressure measurement system.

Dikran Tourian, the CEO of Biozen, expressed his enthusiasm about the award, stating, "Being named the People’s Choice Winner at ACC is a significant moment for our team. It reflects a growing focus on how blood pressure is measured and monitored, and the importance of building solutions that clinicians and consumers can trust." This potent statement underscores the company’s commitment to enhancing diagnostic methods for blood pressure, a crucial aspect of preventive medicine.

Biozen’s flagship product, the BP1000, stands out with its ability to measure absolute blood pressure without the conventional cuff. Thanks to its unique design, which incorporates proprietary pressure and optical sensing along with advanced algorithms, this ultra-compact device measures blood pressure directly from the digital artery at the fingertip. The technology captures arterial occlusion pressure, providing reliable blood pressure readings based on established physiological principles and validated against clinical gold standards.

Omer Inan, the Chief Scientific Officer of Biozen, added, "ACC's Future Hub brings forward technologies that are improving existing approaches to cardiovascular care. Blood pressure measurement is one of the most important tools for preventative medicine, and we believe our technology will play a central role in expanding both screening and monitoring capabilities.” This highlights the growing optimism within the medical community regarding the potential impact of Biozen's technology on cardiovascular health.

In addition to securing the People’s Choice Award, Biozen also showcased prospective clinical validation data at the ACC, adhering to the ISO 81060-2:2018 validation protocol. This rigorous testing further solidifies the credibility of their product in a competitive landscape filled with emerging cardiovascular solutions.

Biozen, headquartered in Oklahoma City and with R&D operations in Atlanta, Georgia, is a privately held digital health company dedicated to innovating medical technologies. The cuffless blood pressure platform is backed by over 70 granted U.S. and international patents, emphasizing Biozen’s commitment to research and development in enhancing cardiovascular diagnostics.

The BP Sensor and BP1000 are still classified as investigational devices and have yet to receive clearance from the U.S. Food and Drug Administration (FDA) for commercial distribution. However, their recognition at ACC 2026 serves as a promising indicator of the device's future potential and the company’s trajectory in improving healthcare solutions.

This award adds to an exciting year for Biozen as it continues to push boundaries in digital health technology and tackle the challenges associated with reliable blood pressure measurement. The company’s innovative contributions are anticipated to play a pivotal role in shaping the future of cardiovascular care.

To learn more about Biozen and its groundbreaking technologies, visit biozen.com.